Valerio Therapeutics' financial and strategic review for the first half of 2025

Valerio Therapeutics has announced a strategic refocusing on preclinical research, marking the end of its clinical activities, including the VIO-01 trial. This shift leverages the V-Body and Integrated Chemistry platforms, which focus on humanized single-domain antibodies and immunoconjugates. This repositioning aims to optimize resources for the discovery of new drug candidates.

In the first half of 2025, the company generated non-recurring revenue of €126,000, reduced its expenses to €2.9 million, and limited its net loss to €208,000, reflecting the impact of restructuring. Cash flow improved thanks to shareholder advances, reaching €2.6 million as of June 30, 2025.

Furthermore, Valerio Therapeutics aims to ensure its financial stability until the end of 2025 through partnerships and non-dilutive financing. The company remains committed to seeking collaborations to maximize the value of its assets prior to clinical trials.